Lifemd Inc Stock Price, News & Analysis

Medifast (NYSE: MED), the company behind the OPTAVIA® health and wellness program, has scheduled its Q2 2025 financial results announcement for August 4, 2025, after market close.

The company will host a conference call at 4:30 p.m. ET featuring Chairman and CEO Dan Chard and CFO Jim Maloney. The call will be available via webcast on Medifast's Investor Relations website and will remain archived through November 3, 2025. Telephone participants can dial (201) 389-0879, with playback access available through August 11, 2025.

LifeMD (Nasdaq: LFMD), a virtual primary care services provider, has announced a quarterly dividend payment for holders of its 8.875% Series A Cumulative Perpetual Preferred Stock (Nasdaq: LFMDP). The company will distribute a cash dividend of $0.5546875 per share. The dividend is payable on July 15, 2025, to shareholders of record as of July 3, 2025.

LifeMD (NASDAQ: LFMD), a virtual primary care services provider, has announced its participation in two major investor conferences in June 2025. The company's management will join a virtual panel discussion on "Direct to Consumer vs. Direct to Enterprise" at the BTIG Obesity Health Forum on June 18 at 2:00 PM ET. Additionally, they will participate in the Truist Securities Healthcare Disruptors & Digital Health Conference at New York City's Park Lane Hotel on June 24-25, where they will discuss "Tailored Approach to Weight Loss Solutions" and be available for one-on-one meetings with institutional investors.

LifeMD (NASDAQ: LFMD) has partnered with Novo Nordisk to launch a limited-time $299 introductory bundle for self-pay patients prescribed Wegovy®. The bundle includes Wegovy® at $199 and LifeMD's virtual weight management program, available until June 30, 2025. After the first month, the program will cost $599 monthly with no long-term commitment required.

The collaboration strengthens LifeMD's ability to deliver FDA-approved GLP-1 medications through an integrated care experience, targeting patients seeking alternatives to compounded therapies. LifeMD's platform provides comprehensive services from virtual consultation to prescription fulfillment and ongoing support. Wegovy® is available through NovoCare® Pharmacy integration for eligible uninsured patients or those whose insurance doesn't cover weight-loss medications.

LifeMD (NASDAQ: LFMD), a virtual primary care services provider, has announced its participation in three major investor conferences in May 2025:

• H.C. Wainwright BioConnect Conference on May 20 at Nasdaq, New York City
• B. Riley Securities Conference on May 21-22 at the Ritz-Carlton, Marina Del Rey, featuring a corporate overview presentation
• Craig-Hallum Conference on May 28 at The Depot Renaissance Minneapolis Hotel

Management will conduct one-on-one meetings with investors at all events, with additional small group meetings at the Craig-Hallum conference.

LifeMD (NASDAQ: LFMD) reported strong Q1 2025 results, with total revenues rising 49% year-over-year to $65.7 million. The company achieved its first-ever quarter of GAAP profitability with net income of $0.6 million ($0.01 per share). Telehealth revenue surged 70% to $52.4 million, with active subscribers growing 22% to 290,000. Adjusted EBITDA improved significantly to $8.7 million from $0.1 million in the year-ago period. Following strong performance, LifeMD raised its full-year 2025 guidance, now expecting total revenues of $268-275 million and adjusted EBITDA of $31-33 million. The company highlighted strategic collaborations with LillyDirect and NovoCare, becoming the only U.S. telehealth provider offering cash-pay access to both Wegovy® and Zepbound®.

LifeMD has announced plans to expand access to Wegovy® (semaglutide) through NovoCare® Pharmacy for cash-pay patients. The company will offer the FDA-approved weight loss medication at a reduced self-pay cost of $499 per month, including home delivery.

Through their virtual care platform, LifeMD provides a comprehensive weight management program featuring:

• Virtual consultations
• Lab testing
• Diet and lifestyle support
• Prescriptions for anti-obesity medications including GLP-1s

The integration with NovoCare® Pharmacy allows direct access to all FDA-approved dose strengths of Wegovy®, which is notably the first GLP-1 therapy approved in the United States for both chronic weight management and cardiovascular risk reduction in adults with obesity. The service targets uninsured patients or those whose insurance doesn't cover prescription weight-loss medications.

LifeMD (Nasdaq: LFMD), a virtual primary care services provider, has scheduled its Q1 2025 financial results announcement for May 6, 2025, after U.S. market close.

The company will host a conference call and webcast at 4:30 p.m. Eastern time to discuss the results for the three months ended March 31, 2025. Interested parties can join through multiple channels:

• Toll-Free: 800-225-9448
• International: 203-518-9708
• Conference ID: LIFEMD

A live webcast will be available, and an archived version will be accessible for replay after the event.

Medifast reported challenging Q1 2025 results with revenue declining 33.8% to $115.7 million. The health and wellness company's OPTAVIA program saw active earning coaches decrease 32.8% to 25,400, compared to 37,800 in Q1 2024.

Key financial highlights:

• Net loss of $0.8 million ($0.07 per share)
• Revenue per active coach at $4,556
• Gross profit down 33.8% to $84.2 million
• Strong balance sheet with $164.6 million in cash and no debt

CEO Dan Chard emphasized that 83% of people seeking weight loss lack confidence in maintaining long-term health improvements. The company is focusing on revitalizing its coach and customer base through enhanced tools and new products. For Q2 2025, Medifast expects revenue between $85-105 million with projected loss per share of $0.00 to $0.55.